Our Commitment to Access
We partner with governments and communities to reduce the disproportionate disease burden in low- and middle-income countries. Our Gilead Patient Solutions (GPS) team operates in countries across the world to champion innovative solutions that improve patient outcomes, promote health system sustainability, strengthen infrastructure and uplift communities.
Long-acting HIV pre-exposure prophylaxis (PrEP) options are critical for people around the world who need additional choices to reduce their chances of acquiring HIV.
Learn About Access to Long-Acting PrEPAddressing the HIV Epidemic
We've long been a leader in HIV treatment and prevention, helping transform HIV from an inevitably fatal condition to a chronic one that can be well managed. We introduced the first once-daily oral medication for pre-exposure prophylaxis (PrEP) to help prevent HIV transmission and continue to advance the next generation of long-acting therapeutic options.
In low- and middle-income countries, we’ve put innovative programs and partnerships in place to expand global access to our HIV medicines. Each year, millions of treatments for HIV, along with hepatitis B, are made available in low- and middle-income countries through our voluntary licensing programs.
To end the HIV epidemic, our approach must evolve to ensure everyone who needs or wants our therapies can access them. We're developing access strategies for many of our next-generation HIV prevention therapies that account for the unique challenges of distributing and integrating them into care.
Learn About Our Work in HIVTreating Viral Hepatitis
More than 300 million people worldwide are living with chronic hepatitis B or C, which can lead to serious and life-threatening liver damage, including liver cirrhosis (scarring), liver cancer and the need for liver transplantation.
While viral hepatitis is one of the leading causes of preventable death globally, the vast majority of people with the disease haven't received high-quality medical treatment and many people with the disease haven't been diagnosed.
We've pioneered a cure for hepatitis C (HCV) and have helped transform hepatitis B (HBV) into a manageable condition as we work toward a cure. We’re collaborating with regional partners and generic licensees to introduce our HCV and HBV therapies in low- and middle-income countries, prioritizing communities with the greatest disease burden.
We’re also going beyond medicine to help address the disparities impacting people living with viral hepatitis. Through our corporate giving programs, we partner with community organizations working to ensure people around the world receive high-quality care and services.
Learn About Our Work in Viral HepatitisResponding to Viral Threats
We envision a future where our supply chain—optimized for speed and reach—enables us to activate countermeasures against emerging and neglected viral threats before they escalate into global crises.
Drawing on our long history in HIV and hepatitis, we are uniting our scientific expertise with global access to protect communities from viruses such as Ebola, Marburg, dengue and COVID-19.
With a focus on advancing solutions for urgent global health challenges, we work closely with health authorities to accelerate evidence generation, regulatory pathways, and responsible deployment.
To ensure access as quickly as possible, we enable voluntary licensing in high-incidence, resource-limited countries, support rapid technology transfers, and maintain reliable supply through regional production and data-driven forecasting.
Eliminating Invasive Fungal Infections
We champion innovative solutions that improve patient outcomes and uplift communities worldwide. Our work to address invasive fungal infections began more than three decades ago when we launched a partnership with the World Health Organization (WHO) to combat visceral leishmaniasis (VL), a debilitating parasitic disease, and provide our treatment at a no-profit price in low- and middle-income countries.
Learn MoreAccess Partnerships
We work with a network of regional distributors to enable access to our portfolio of medicines in low- and middle-income countries. We also collaborate with voluntary licensees, the Medicines Patent Pool and other stakeholders to expand access to our medicines around the world. Together, we're relentlessly working to address critical health inequities worldwide.
Learn More